We are excited to be hosting another Scottish Network Event in Edinburgh, UK this September.
Novel Approach Methodologies (NAMs) are creating new opportunities to generate more human relevant evidence for advanced therapy development, supporting better translational decision making while helping to reduce reliance on traditional animal models where they are not feasible, proportionate or sufficiently predictive.
For complex and rapidly evolving therapies, timely access to relevant evidence is critical. NAMs offer alternative and complementary ways to strengthen evidence packages, improve confidence in candidate selection and support progression towards the clinic.
This Scottish Advanced Therapies Network event will bring together companies, academics and development partners from across Scotland to explore where NAMs are already adding value, what challenges remain, and how Scotland’s advanced therapies ecosystem can better connect model development, translational science, manufacturing, safety assessment and regulatory strategy.
Agenda
16:30 – 17:00 | Registration
17:00 – 17:10 | Welcome and Opening Remarks
17:10 – 17:30 | Human-relevant models for translational decision making
Hazel Paulo, Study Director, Charles River Laboratories
17:30 – 17:50 | Engineering improved NAM platforms
Matthew Dalby, Director of the Centre for the Cellular Microenvironment and Professor of Cell Engineering at The University of Glasgow
17:50 – 18:10 | Applying human-relevant NAMs to advanced therapy clinical safety assessment
Anne Dickinson, Founder and CEO, Alcyomics and Emerita Professor in the Translational and Clinical Research Institute, Newcastle University
18:10 – 18:30 | Positioning NAMs within the advanced therapy evidence package
Mark Singh, Senior Non-Clinical Manager, Cell and Gene Therapy Catapult
18:30 – 19:00 | Panel discussion. Integrating NAMs into practice: evidence generation, development and release
All speakers
19:00 - 19:45 | Networking Drinks Reception
Who should attend?
This event is open to professionals across the advanced therapies and life sciences sectors who are interested in how novel non-clinical methodologies can support more human-relevant evidence generation, translational decision-making and the future development of ATMPs.